<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mendiz, Oscar A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RDN: Its Current Place in the Treatment of Resistant Hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-27 10:52:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Renal denervation is a promising strategy to treat true treatment-resistant hypertension. However, careful patient selection is required, by a cardiac team using well-defined criteria. Renal denervation should only be performed in an experienced catheterization laboratory performing at least 14 ablations a year. Promising results have been obtained with new ablation devices.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>